ArticleiScience2021
Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents.
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Molecular profiling of coronary stent testenosis: A systematic review and functional analysis of implicated genes.Medicine · 2026Pooled it
- Beyond Angiography: Integrating Advanced Diagnostic Modalities in Coronary Stent Restenosis-a Systematic Review.International journal of medical sciences · 2026Pooled it
- A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention.BMC cardiovascular disorders · 2024Pooled it
- The association between glycated hemoglobin levels and in-stent restenosis following percutaneous coronary intervention in coronary artery disease patients.Frontiers in endocrinology · 2026Article
- Application of genetic risk score for in-stent restenosis of second- and third-generation drug-eluting stents in geriatric patients.BMC geriatrics · 2023Article
- Genetic Variants in PHACTR1 & LPL Mediate Restenosis Risk in Coronary Artery Patients.Vascular health and risk management · 2023Article
- Bioimpedance Sensing of Implanted Stent Occlusions: Smart Stent.Biosensors · 2022Article
- Role of Glycosylation in Vascular Calcification.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new generation, i.e., second- and third-generation, drug-eluting stents (DESs) remain a risk of in-stent restenosis (ISR). We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation DES ISR. We enrolled patients with coronary artery disease (CAD) treated with new generations DESs by a single-center cohort study in Taiwan and evaluated their genetic profile. After propensity score matching, there were 343 patients and 153 patients in the derivation and validation cohorts, respectively. Five selected single-nucleotide polymorphisms (SNPs), i.e., SNPs in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.